The Heart Failure Pipeline report embraces in-depth commercial and clinical assessment of the Heart Failure pipeline products from the pre-clinical developmental phase to the marketed phase.
The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, mergers, acquisition, funding, designations, and other product-related details.
Get FREE sample copy at: https://www.delveinsight.com/sample-request/heart-failure-pipeline-insight
As per the DelveInsight, owing to the launch of upcoming therapies, the Heart Failure market size shall increase during the forecast period.
Heart Failure Companies:
Eli Lilly and Company
Merck Sharp & Dohme Corp.
And many others.
Heart Failure Therapies Covered in the report include:
Entresto (sacubitril and valsartan)
And many more.
The report provides insights into:
The report provides detailed insights about companies that are developing therapies for the treatment of Heart Failure with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late stage of development for the Heart Failure Treatment.
Heart Failure key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Heart Failure market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Scope of the report
The Heart Failure Pipeline Report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Heart Failure across the complete product development cycle, including all clinical and non-clinical stages.
It comprises detailed profiles of Heart Failure therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Detailed research and development progress and clinical trial of Heart Failure, results wherever available, are also included in the pipeline study.
Coverage of dormant and discontinued pipeline projects along with the reasons if available across Heart Failure.
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Heart Failure.
In the coming years, the Heart Failure market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure Research & Development. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Heart Failure treatment market. Several potential therapies for Heart Failure are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Heart Failure market size in the coming years.
Our in-depth analysis of the Heart Failure pipeline assets (in early-stage, mid-stage, and late stage of development) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Table of Content
1. Report Introduction
2. Heart Failure
3. Heart Failure Current Treatment Patterns
4. Heart Failure – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Heart Failure Late Stage Products (Phase-III)
7. Heart Failure Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Heart Failure Discontinued Products
13. Heart Failure Product Profiles
14. Heart Failure Key Companies
15. Heart Failure Key Products
16. Dormant and Discontinued Products
17. Heart Failure Unmet Needs
18. Heart Failure Future Perspectives
19. Heart Failure Analyst Review
21. Report Methodology
*The table of contents is not exhaustive; the final content may vary.
Latest Reports By DelveInsight
Heart Failure Market Insight
DelveInsight’s “Heart Failure Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as Heart Failure market size, share, and trend analysis for the 7MM (i.e the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan).
Healthcare Blogs –
Cancer Anorexia Market Growth
The incidence of anorexia by cancer types (in advanced cancers, namely, colorectal cancer, lung cancer, pancreatic cancer, head and neck cancer, gastroesophageal cancer, and liver cancer) in the 7MM (the US, EU5 and Japan) was recorded to be 740,055 in 2020, which is further anticipated to increase during the forecast period. As per the DelveInsight, the expected launch of pipeline therapies by key players such as Helsinn Group, Artelo Biosciences, and NGM Biopharmaceuticals will accelerate the Cancer Anorexia market growth at a CAGR of 10.92% for the forecast period 2021-30.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States